Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-25T18:17:51.604Z Has data issue: false hasContentIssue false
  • English
  • Français

Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study

Published online by Cambridge University Press:  16 April 2020

R Shiloh ,
Z Zemishlany ,
D Aizenberg  and
A Weizman
R Shiloh
Affiliation:
Geha Psychiatric Hospital, Petah Tikva, and Sackler Faculty of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
Z Zemishlany
Affiliation:
Geha Psychiatric Hospital, Petah Tikva, and Sackler Faculty of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
D Aizenberg
Affiliation:
Geha Psychiatric Hospital, Petah Tikva, and Sackler Faculty of Medicine, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
Get access

Summary

Six chronic neuroleptic-resistant schizophrenic patients, partial responders to clozapine, were co-administered 600 mg/day of sulpiride (a selective D2 dopaminergic antagonist) as an augmentation to clozapine (a relatively weak D2 blocker), for 10 weeks, open-labeled. A remarkable reduction in positive and negative symptoms was observed in four of the six patients.

Keywords

schizophreniaclozapinesulpiridedopamineprolactin
Type
Case report
Information
European Psychiatry , Volume 12 , Issue 3 , 1997 , pp. 152 - 155
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, NCScale for the Assessment of Negative Symptoms (SANS). London: The University of Iowa, 1983Google Scholar
Andreasen, NCScale for the Assessment of Positive Symptoms (SANS). Iowa City: The University of Iowa, 1984Google Scholar
Casey, DEGerlach, JSulpiride in tardive dyskinesia. Psychopharmacology (Berlin) 1979; 66: 73–77CrossRefGoogle ScholarPubMed
Cassano, GBCastrogiovanni, PConti, LSulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Curr Ther Res 1975; 17: 189–201Google ScholarPubMed
Edwards, JGAlexander, JRAlexander, MSGordon, AZutchi, TControlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 1980; 137: 522–529CrossRefGoogle ScholarPubMed
Farmer, AEBlewett, ADrug treatment of resistant schizophrenia. Drugs 1993; 45: 374–383CrossRefGoogle ScholarPubMed
Gudelsky, GANash, JFBerry, SABasic biology of clozapine. Electrophysiological and neuroendocrinological studies. Psychopharmacology (Berlin) 1989; 99: 513–517CrossRefGoogle ScholarPubMed
Hamilton, MA rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62CrossRefGoogle ScholarPubMed
Hamryd, CBjerkenstedt, LBjork, KGullbers, BOxenstierna, GSedvall, GWiesel, FAWik, GAberg-Wistedt, AClinical evaluation of sulpiride in schizophrenic patients - A double-blind comparison with chlorpromazine Acta Psychiatr Scand 1984 69 suppl 311 7–30Google Scholar
Kane, JClinical efficacy of clozapine in treatment of refractory schizophrenia: an overview Br J Psychiatry 1992 18 suppl 17 41–45CrossRefGoogle Scholar
Kane, JHonigfeld, GSinger, JMeltzer, HClozapine for the treatment of resistant schizophrenia. Arch Gen Psychiatry 1988; 45: 789–796CrossRefGoogle Scholar
Lieberman, JSaltz, BJohns, CPollak, SBorentein, MKane, JThe effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503CrossRefGoogle ScholarPubMed
Mielke, DHGallant, DMRoniger, JJKessler, CKessler, LRSulpiride: evaluation of antipsychotic activity in schizophrenic patients. J Nerv Ment Dis 1977; 38: 569–571Google ScholarPubMed
Moriuchi, KImazu, YYoneda, HDifferences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res 1995; 20: 95–99CrossRefGoogle ScholarPubMed
Nishiura, MClinico-pharmacological studies of sulpiride. Curr Ther Res 1976; 20: 164–172Google ScholarPubMed
Niskanen, PTamminen, TViukari, MSulpiride versus amitryptyline in the treatment of depression. Curr Ther Res 1975; 17: 281Google Scholar
Overall, JEGorham, DEThe brief psychiatric rating scale. Psychol Rep 1961; 10: 799–812CrossRefGoogle Scholar
Pickar, DOwen, RRLitman, REHisiao, JKSu, TPPredictors of clozapine response in schizophrenia. J Clin Psychiatry 1994; 55: 129–132Google Scholar
Pucak, MLGrace, AAEvidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 1994; 271: 1181–1192Google ScholarPubMed
Tamminga, CAGerlach, JNew neuroleptics and experimental anti psychotics in schizophrenia In: Meltzer, HYPsychopharmacology, the Third Generation of Progress Iowa City: Raven Press, 1987; 1130–1132Google Scholar
Submit a response

Comments

No Comments have been published for this article.